SILMA Silmaasema OYJ

Silmäasema Oyj: Interim Report 1 January–31 March 2019: Silmäasema’s net sales and adjusted EBITDA increased in January-March

Silmäasema Oyj: Interim Report 1 January–31 March 2019: Silmäasema’s net sales and adjusted EBITDA increased in January-March

Silmäasema Oyj Interim Report 1 January–31 March 2019

Silmäasema Oyj           

Stock Exchange Release                      

17 May 2019 at 8:00 a.m. EET

Silmäasema’s net sales and adjusted EBITDA increased in January-March

January–March 2019 in brief

  • Net sales increased by 4.3% compared to January–March 2018, amounting to EUR 32.2 million (30.9). Like-for-like net sales grew by 1.8%.
  • The adjusted EBITDA* increased by 87.6% and was EUR 5.2 million (2.8), or 16.3% of net sales (9.1%). Without the impact of IFRS 16 the adjusted EBITDA would have been 10.5% of net sales.
  • The adjusted operating result* increased by 37.9% to EUR 1.9 million (1.4).
  • Cash flows from operating activities* performed strongly and amounted to EUR 7.0 million (4.4).
  • The net debt* at the end of the period was EUR 50.1 million (32.7)
  • The net debt to adjusted EBITDA ratio* on 31 March 2019 was 3.5 (2.8)

The figures for 2018 are from the audited Financial Statements. The quarterly figures are unaudited. The figures in parenthesis refer to the comparable period in 2018, and “comparison period” refers to the comparable period in the previous year, unless otherwise mentioned.

Outlook for 2019 unchanged

Silmäasema expects its full-year like-for-like net sales to be at the previous year’s level and its adjusted EBITDA margin to be at the previous year’s level or slightly better (2018:  9.6%), excluding the effect of the IFRS 16 standard, which was adopted at the beginning of 2019.



* IFRS 16 affects the comparability of reported figures

Silmäasema adopted the IFRS 16 Leases standard that entered into force on 1 January 2019 at the start of the financial period.  The figures reported for January-March 2019 are not comparable with the figures for the comparison period, as they include items based on the adoption of IFRS 16. The impact of the adoption of IFRS 16 on key ratios is presented in the key figures in the table “Impact of IFRS 16 on key figures”. Comparative period data in parenthesis have not been amended in accordance with IFRS 16 standard. There is more information on this in Note 5.3 to the Interim Report on pages 27-28.

 

Key figures

EUR thousand, unless otherwise stated1–3/20191–3/2018Change, %1–12/2018
Net sales32,19130,8704.3 %122,873
Like-for-like net sales growth, %1.8 %-2.4 % -1.6 %
EBITDA5,1872,520105.8 %11,443
Adjusted EBITDA*5,2482,79787.6 %11,765
- adjusted EBITDA, %16.3 %9.1 % 9.6 %
Operating result1,8741,11867.7 %5,492
Adjusted operating result*1,9391,40637.9 %5,844
- adjusted operating result, %6.0 %4,6 % 4.8 %
Basic earnings per share, EUR0.070.04 0.23
Net debt / adjusted EBITDA3.52.8 2.4
Investments – operational1553,107-95.0 %6,716
Investments – acquisitions496694-28.5 %1,775
Investments – total6513,801-82.9 %8,491
Number of locations, Silmäasema chain179177 181

*) The key figure is not comparable due to the IFRS 16 standard that was adopted at the beginning of 2019.

**) Silmäasema presents both its adjusted EBITDA and adjusted operating result, which have been adjusted for significant extraordinary items. It is the company’s view that the adjusted EBITDA best illustrates the profitability development of its business operations.

Impact of IFRS 16 on key figures

EUR thousand, unless otherwise statedReported

1-3/2019
Excluding

 IFRS 16


1-3/2019
Effect of

 IFRS 16

adoption
Reported

1-3/2018
EBIDTA5,1873,3251,8622,520
Adjusted EBITDA5,2483,3861,8622,797
Adjusted EBITDA, %16.3 %10.5 %+5,8 p.p.9.1 %
Operating result1,8741,802731,118
Adjusted operating result1,9391,867731,406
Profit before taxes1,3811,483-102775
Profit for the period1,0091,091-82516
Earnings per share (EPS) undiluted, EUR0.070.08-0.010.04
Cashflow from operations6,9705,2831,6874,386
Net debt50,10022,88527,21532,703
Net debt / Adjusted EBITDA (leverage)3.51.9 2.8
Gearing116.4 %53.1 %+63.4 p.p.83.1 %
Equity Ratio34.6 %44.3 %-9.7 p.p.40.3 %
Return on Capital Employed, % (ROCE)1.7 %2.3 %-0.5 % p.p.1.4 %
Return on equity, % (ROE)2.4 %2.6 %-0.2 % p.p.1.3 %

 

CEO Jussi Salminen:

“Silmäasema’s net sales and adjusted EBITDA improved on the previous year in January-March. In Optical retail we succeeded well throughout the network and group’s net sales increased overall by 4.3% to EUR 32.2 million, and our like-for-like net sales grew by 1.8%. Eye Clinics suffered from lower volumes than the previous year.

As part of our development programme we have identified opportunities to streamline our operations and optimise our cost structure outside our personnel expenses. We estimate the potential impact on profit of the identified opportunities to be approximately EUR 2 million. This would be achieved gradually by the end of 2020. In part, the impact can already be seen in the result for the first quarter.

Our financial reporting was updated at the beginning of the year to comply with the IFRS 16 Leases standard and this has had an impact on, among other things, the reported and adjusted EBITDA since the beginning of the year. Reported according to the new standard, the first-quarter adjusted EBITDA was EUR 5.2 million including the EUR 1.9 million impact of the adoption of the IFRS 16 standard. Excluding the impact of the adoption of IFRS 16 standard, the adjusted EBITDA improved by 21% on the comparison period.

The Group’s cash flows from operating activities developed exceptionally well and increased almost 60% to EUR 7.0 million.  The impact of the adoption of the IFRS 16 standard was EUR 1.7 million. Despite the growth of net sales and the network, our fixed costs remained at the level of the comparison period excluding the impact of the IFRS 16 standard.

In Optical Retail net sales increased by 9.5% to EUR 23.2 million. We managed to increase our sales while retaining a good gross profit margin. The segment’s adjusted EBITDA improved by 58%, excluding the effect of the adoption of the IFRS 16 standard. As we have previously communicated, we develop our network in a customer-focused manner and as the year progresses, we systematically make changes to the locations of stores, their opening times and the services they offer. The development of the network includes the evaluation of our Estonian operations as a whole in addition to our Finnish operations. Active development of the network of locations also includes store closures and openings.

The Eye Clinics segment’s net sales declined 7.2% to EUR 8.9 million and this reflected directly on the segment’s profitability. The segment’s adjusted EBITDA declined 20%, excluding the effect of the adoption of the IFRS 16 standard. In our view there has not been any significant change in the size of the total refractive and cataract surgery market in Finland. We have analysed the reasons for the decline in the number of procedures and have launched our first steps to improve the volumes. These include, among others, boosting customer acquisition, strengthening cross-selling, and developing cooperation with our doctors.

In 2019, we will focus more on improving productivity. Our priorities for the current year are improving the operational preconditions, developing our network and improving profitable growth. In addition, we have launched a strategy process during the review period, the results of which we will report more in the second half of the year.

Our staff through the organization has done a lot of work and achieved good results together in the early part of the year. As a whole, we are pleased with both the results of the early part of the year and the progress of this year's priorities.”

 

Audiocast and conference call for analysts and media

A briefing for investment analysts and the media will be arranged on Friday 17 May 2019 at 10:30 a.m. EET through a live audiocast combined with a conference call. The briefing will be hosted by CEO Jussi Salminen and CFO Anu Kankkunen.

Follow the live audiocast at

Conference call numbers:

Finland                  +358 (0) 981 710 310

UK                          4

USA                       

Sweden                

The participants joining the conference call will be asked to provide the following PIN code: 38780004#

Recording of the audiocast and conference call as well as Finnish audiocast presentations will be later available on the company’s website.

 

Silmäasema’s Financial Reporting in 2019

Half Year Financial Report                          16 August 2019

Interim Report January – September          8 November 2019

 

SILMÄASEMA OYJ

Board of Directors

 

 

Additional information

CEO Jussi Salminen, tel. +358 40 834 5818, jussi.m.salminen(a)silmaasema.fi

CFO Anu Kankkunen, tel. , anu.kankkunen(a)silmaasema.fi

Acting Head of Communications and Investor Relations Mikko Merisaari, tel. 5, mikko.merisaari(a)silmaasema.fi

 

Silmäasema is a Finnish company, which offers all products and services for optical retail and eye healthcare nationwide. Silmäasema is the largest private eye clinic provider offering eye surgeries and the second largest optical retail chain in Finland. The Silmäasema chain has over 150 stores and 14 eye clinics in Finland as well as ten stores in Estonia. The Silmäasema chain employs over 700 eye healthcare professionals. Silmäasema's Group net sales were EUR 122,9 million in 2018 and adjusted EBITDA was EUR 11.8 million.

 

Attachment

EN
17/05/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Silmaasema OYJ

 PRESS RELEASE

Silmäasema Oyj: Coronaria Oy Has Gained Title to All the Shares in Si...

Silmäasema Oyj: Coronaria Oy Has Gained Title to All the Shares in Silmäasema Oyj and the Shares Have Been Delisted from Nasdaq Helsinki Coronaria Oy Has Gained Title to All the Shares in Silmäasema Oyj and the Shares Have Been Delisted from Nasdaq Helsinki Silmäasema Oyj Stock Exchange Release – Tender Offer 5 May 2020 at 4:00 p.m. EEST Coronaria Oy (“Coronaria”) has today placed security approved by the Arbitral Tribunal and thus gained title to all the shares in Silmäasema Oyj (“Silmäasema”) in accordance with Chapter 18, Section 6 of the Finnish Companies Act. After the security has...

 PRESS RELEASE

Silmäasema Oyj: Coronaria Oy on saanut omistusoikeuden Silmäasema Oy...

Silmäasema Oyj: Coronaria Oy on saanut omistusoikeuden Silmäasema Oyj:n kaikkiin osakkeisiin ja osakkeet ovat poistuneet Nasdaq Helsingin pörssilistalta Coronaria Oy on saanut omistusoikeuden Silmäasema Oyj:n kaikkiin osakkeisiin ja osakkeet ovat poistuneet Nasdaq Helsingin pörssilistalta Silmäasema Oyj                    Pörssitiedote – julkinen ostotarjous                                   5.5.2020 klo 16.00 Coronaria Oy (”Coronaria”) on tänään asettanut välimiesoikeuden hyväksymän vakuuden ja näin ollen saanut omistusoikeuden kaikkiin Silmäasema Oyj:n (”Silmäasema”) osakkeisiin osa...

 PRESS RELEASE

Silmäasema Oyj: Arbitral Tribunal Has Confirmed Coronaria Oy's Redemp...

Silmäasema Oyj: Arbitral Tribunal Has Confirmed Coronaria Oy's Redemption Right to Silmäasema Oyj's Shares and Trading in Silmäasema’s Shares Has Been Suspended Arbitral Tribunal Has Confirmed Coronaria Oy's Redemption Right to Silmäasema Oyj's Shares and Trading in Silmäasema’s Shares Has Been Suspended Silmäasema Oyj Stock Exchange Release – Tender Offer 28 April 2020 at 9:50 a.m. EEST The Arbitral Tribunal appointed by the Redemption Committee of the Finland Chamber of Commerce has on 27 April 2020 confirmed that Coronaria Oy (“Coronaria”) has the right to redeem the minority shares ...

 PRESS RELEASE

Silmäasema Oyj: Välimiesoikeus on vahvistanut Coronaria Oy:n lunastu...

Silmäasema Oyj: Välimiesoikeus on vahvistanut Coronaria Oy:n lunastusoikeuden Silmäasema Oyj:n osakkeisiin ja kaupankäynti Silmäaseman osakkeilla on keskeytetty Välimiesoikeus on vahvistanut Coronaria Oy:n lunastusoikeuden Silmäasema Oyj:n osakkeisiin ja kaupankäynti Silmäaseman osakkeilla on keskeytetty Silmäasema Oyj                    Pörssitiedote – julkinen ostotarjous                                   28.4.2020 klo 9.50 Keskuskauppakamarin lunastuslautakunnan nimittämä välimiesoikeus on 27.4.2020 vahvistanut, että Coronaria Oy:llä (”Coronaria”) on oikeus lunastaa Silmäasema Oyj:n...

 PRESS RELEASE

Silmäasema Oyj: Silmäasema Oyj Applies for Delisting of Its Shares f...

Silmäasema Oyj: Silmäasema Oyj Applies for Delisting of Its Shares from Nasdaq Helsinki Silmäasema Oyj Applies for Delisting of Its Shares from Nasdaq Helsinki Silmäasema Oyj Stock Exchange Release – Inside information 16 April 2020 at 4:05 p.m. EET Silmäasema Oyj’s (“Silmäasema”) Board of Directors has decided to apply for the termination of public trading in Silmäasema shares and the delisting of Silmäasema’s shares from the official list of Nasdaq Helsinki Ltd (“Nasdaq Helsinki”). Coronaria Oy (“Coronaria”) owns more than nine tenths (9/10) of all the shares and votes in Silmäasema a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch